Source:http://linkedlifedata.com/resource/pubmed/id/17957541
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2008-3-13
|
pubmed:abstractText |
The objective of this study was to determine whether administration of a catalytic antioxidant, Mn(III) tetrakis(N,N'-diethylimidazolium-2-yl) porphyrin, AEOL10150, reduces the severity of long-term lung injury induced by fractionated radiation (RT). Fisher 344 rats were randomized into five groups: RT+AEOL10150 (2.5 mg/kg BID), AEOL10150 (2.5 mg/kg BID) alone, RT+ AEOL10150 (5 mg/kg BID), AEOL10150 (5 mg/kg BID) alone and RT alone. Animals received five 8 Gy fractions of RT to the right hemithorax. AEOL10150 was administered 15 min before RT and 8 h later during the period of RT treatment (5 days), followed by subcutaneous injections for 30 days, twice daily. Lung histology at 26 weeks revealed a significant decrease in lung structural damage and collagen deposition in RT+AEOL10150 (5 mg/kg BID) group, in comparison to RT alone. Immunohistochemistry studies revealed a significant reduction in tissue hypoxia (HIF1alpha, CAIX), angiogenic response (VEGF, CD-31), inflammation (ED-1), oxidative stress (8-OHdG, 3-nitrotyrosine) and fibrosis pathway (TGFbeta1, Smad3, p-Smad2/3), in animals receiving RT+ AEOL10150 (5 mg/kg BID). Administration of AEOL10150 at 5 mg/kg BID during and after RT results in a significant protective effect from long-term RT-induced lung injury. Low dose (2.5 mg/kg BID) delivery of AEOL10150 has no beneficial radioprotective effects.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1071-5762
|
pubmed:author |
pubmed-author:AnscherMitchell SMS,
pubmed-author:Batinic-HaberleInesI,
pubmed-author:DewhirstMark WMW,
pubmed-author:Gauter-FleckensteinBenjaminB,
pubmed-author:RabbaniZahid NZN,
pubmed-author:SalahuddinFawzia KFK,
pubmed-author:ThrasherBradley ABA,
pubmed-author:VujaskovicZeljkoZ,
pubmed-author:YarmolenkoPavelP
|
pubmed:issnType |
Print
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1273-82
|
pubmed:meshHeading |
pubmed-meshheading:17957541-Animals,
pubmed-meshheading:17957541-Antioxidants,
pubmed-meshheading:17957541-Catalysis,
pubmed-meshheading:17957541-Cytoprotection,
pubmed-meshheading:17957541-Dose Fractionation,
pubmed-meshheading:17957541-Dose-Response Relationship, Drug,
pubmed-meshheading:17957541-Drug Evaluation, Preclinical,
pubmed-meshheading:17957541-Female,
pubmed-meshheading:17957541-Lung,
pubmed-meshheading:17957541-Lung Diseases,
pubmed-meshheading:17957541-Metalloporphyrins,
pubmed-meshheading:17957541-Models, Biological,
pubmed-meshheading:17957541-Molecular Weight,
pubmed-meshheading:17957541-Radiation Injuries, Experimental,
pubmed-meshheading:17957541-Random Allocation,
pubmed-meshheading:17957541-Rats,
pubmed-meshheading:17957541-Rats, Inbred F344
|
pubmed:year |
2007
|
pubmed:articleTitle |
Low molecular weight catalytic metalloporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation.
|
pubmed:affiliation |
Department of Radiation Oncology, Durham Regional Hospital/Duke University Medical Center, Durham, NC 27710, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|